Goldman Sachs
CADL icon

Goldman Sachs’s Candel Therapeutics CADL Stock Holding History

Goldman Sachs’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
227,521
+162,436
+250% +$884K ﹤0.01% 5024
2025
Q4 		$368K Buy
65,085
+29,064
+81% +$156K ﹤0.01% 5769
2025
Q3 		$184K Sell
36,021
-43,384
-55% -$251K ﹤0.01% 5973
2025
Q2 		$402K Buy
79,405
+24,739
+45% +$127K ﹤0.01% 5288
2025
Q1 		$309K Sell
54,666
-10,570
-16% -$86.4K ﹤0.01% 5442
2024
Q4 		$566K Buy
65,236
+34,975
+116% +$207K ﹤0.01% 5178
2024
Q3 		$210K Buy
30,261
+12,036
+66% +$74.8K ﹤0.01% 5438
2024
Q2 		$113K Buy
+18,225
New +$137K ﹤0.01% 5389
2022
Q3 		– Sell
-10,037
Closed -$33K – 6281
2022
Q2 		$33K Sell
10,037
-473
-5% -$1.89K ﹤0.01% 6104
2022
Q1 		$53K Sell
10,510
-83
-0.8% -$412 ﹤0.01% 6260
2021
Q4 		$83K Buy
+10,593
New +$103K ﹤0.01% 6173

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's CADL Position: Q1 2026 in Review

Goldman Sachs increased its Candel Therapeutics (CADL) stake by 250% in Q1 2026, buying an estimated $884K and bringing the position to 227,521 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #5024.

Goldman Sachs first reported a position in CADL in Q4 2021 and has held it in 11 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Goldman Sachs held 227,521 shares of Candel Therapeutics worth $1.11M as of Q1 2026.
  • Goldman Sachs bought 162,436 Candel Therapeutics shares in Q1 2026, an estimated $884K.
  • Candel Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5024 holding.
  • Goldman Sachs first reported a position in Candel Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.